Sandoz too quick off the mark in Amgen suit: US court

09-12-2014

Sandoz too quick off the mark in Amgen suit: US court

GlebStock / Shutterstock.com

Novartis’s generic arm Sandoz has failed to win a patent case regarding its biosimilar version of Amgen’s psoriasis and arthritis drug Enbrel (etanercept).   


Sandoz, Amgen, Enbrel, biosimilar, US Court of Appeals for the Federal Circuit, Novartis, patent

LSIPR